IMPORTANT SAFETY INFORMATION
VEREGEN® has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.
Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and vesicular rash.
VEREGEN® (sinecatechins) is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Content developed and sponsored by PharmaDerm, a division of Fougera Pharmaceuticals Inc. © 2017 PharmaDerm. All rights reserved.
Veregen® is a registered trademark of Medigene AG, D-82152 Planegg/Martinsried, Germany.
Dr. Gary Goldenberg is a paid consultant for PharmaDerm.